Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oruka Therapeutics reported positive Week 16 results from the EVERLAST-B Phase 2b trial of ORKA-001 in moderate-to-severe psoriasis, with 61% of high-dose (600 mg) patients achieving PASI 100 versus 0% on placebo (p<0.0001). Secondary endpoints were similarly strong, with 86% PASI 90 and IGA 0/1 in the high-dose group, consistent with prior EVERLAST-A results; safety remained consistent with the IL-23p19 class and showed no dose-dependent adverse-event trends.
Key figures
- Drug Name
- ORKA-001
- Phase Of Trial
- Phase 2b
- Enrollment
- 187
- Trial sites
- 36
- Pasi100 placebo
- 0%
- Pasi90 high dose
- 86%
- Iga 0 1 high dose
- 86%
- Pasi100 high dose
- 61%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.